Additionally, FATE1 could be relevant also in other tumors as it has been reported that its silencing increased sensitivity of the NCI-H1155 NSLC cell line to paclitaxel and reduced the viability of a variety of other cancer cell lines. This evidence concerns the gene FATE1 and cancer.